181 related articles for article (PubMed ID: 38057816)
21. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
Zhang P; He M; Zeng Y; Cai X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
[TBL] [Abstract][Full Text] [Related]
22. SOCS7/HuR/FOXM1 signaling axis inhibited high-grade serous ovarian carcinoma progression.
Du Y; Xu X; Lv S; Liu H; Sun H; Wu J
J Exp Clin Cancer Res; 2022 May; 41(1):185. PubMed ID: 35624501
[TBL] [Abstract][Full Text] [Related]
23. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
[TBL] [Abstract][Full Text] [Related]
24. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
[TBL] [Abstract][Full Text] [Related]
25. Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage.
Salvi A; Amrine CSM; Austin JR; Kilpatrick K; Russo A; Lantvit D; Calderon-Gierszal E; Mattes Z; Pearce CJ; Grinstaff MW; Colby AH; Oberlies NH; Burdette JE
Mol Cancer Ther; 2020 Jan; 19(1):89-100. PubMed ID: 31909733
[TBL] [Abstract][Full Text] [Related]
26. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
[TBL] [Abstract][Full Text] [Related]
27. Low expression level of HMBOX1 in high-grade serous ovarian cancer accelerates cell proliferation by inhibiting cell apoptosis.
Yu YL; Diao NN; Li YZ; Meng XH; Jiao WL; Feng JB; Liu ZP; Lu N
Biochem Biophys Res Commun; 2018 Jun; 501(2):380-386. PubMed ID: 29709478
[TBL] [Abstract][Full Text] [Related]
28. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
[TBL] [Abstract][Full Text] [Related]
30. Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-β-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ.
Zhou T; Luo M; Cai W; Zhou S; Feng D; Xu C; Wang H
EBioMedicine; 2018 May; 31():217-225. PubMed ID: 29759484
[TBL] [Abstract][Full Text] [Related]
31. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
[TBL] [Abstract][Full Text] [Related]
32. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
33. LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
Wang Z; Yin P; Sun Y; Na L; Gao J; Wang W; Zhao C
Gynecol Oncol; 2020 Dec; 159(3):839-849. PubMed ID: 32980127
[TBL] [Abstract][Full Text] [Related]
34. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.
Park SH; Song JY; Kim YK; Heo JH; Kang H; Kim G; An HJ; Kim TH
Int J Oncol; 2014 Mar; 44(3):637-46. PubMed ID: 24378809
[TBL] [Abstract][Full Text] [Related]
35. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
[TBL] [Abstract][Full Text] [Related]
36. Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology.
Brown Y; Hua S; Tanwar PS
Matrix Biol; 2023 Apr; 118():16-46. PubMed ID: 36781087
[TBL] [Abstract][Full Text] [Related]
37. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
38. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
Guo Q; Wang L; Zhu L; Lu X; Song Y; Sun J; Wu Z; Shi J; Wang Z; Zhou X
Gene; 2019 Sep; 713():143969. PubMed ID: 31299360
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
Wada M; Kukita A; Sone K; Hamamoto R; Kaneko S; Komatsu M; Takahashi Y; Inoue F; Kojima M; Honjoh H; Taguchi A; Kashiyama T; Miyamoto Y; Tanikawa M; Tsuruga T; Mori-Uchino M; Wada-Hiraike O; Osuga Y; Fujii T
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339442
[TBL] [Abstract][Full Text] [Related]
40. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
